3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Gastrointestinal
1
Conditions
Neoplasms
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Stress Disorders, Post-Traumatic
1
Prostatic Neoplasms
1
Ovarian Neoplasms
1
Myelodysplastic Syndromes
1
Leukemia, Myeloid, Acute
1
Kidney Neoplasms
1
Hematologic Neoplasms
1
Colorectal Neoplasms
1
Interventions
Cyclophosphamide
9
fludarabine
8
Interleukin-2
8
aldesleukin
7
Sunitinib
6
Everolimus
6
Bevacizumab
6
fludarabine phosphate
5
Sorafenib
5
Radiotherapy
4
Nivolumab
4
Gene Expression Profiling
4
Filgrastim
4
pembrolizumab
3
peginterferon alfa-2b
3
Stem Cell Transplantation
3
Radiotherapy, Intensity-Modulated
3
Peripheral Blood Stem Cell Transplantation
3
Melphalan
3
Immunohistochemistry
3
Granulocyte Colony-Stimulating Factor
3
cabozantinib
2
atezolizumab
2
Thiotepa
2
Sodium Chloride
2
Reverse Transcriptase Polymerase Chain Reaction
2
Polymerase Chain Reaction
2
Mycophenolic Acid
2
Mesna
2
Immunoenzyme Techniques
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Kidney Neoplasms
×
Palliative Care
×
Clear all
NCT03652298
2026-03-13
NeuroPrevPTSD
Centre Oscar Lambret
Phase 2
Terminated
19 enrolled